Cancer continues to be one of the most serious and most confounding diseases that medical science battles. Plymouth-based HistoSonics is developing a promising new weapon. It harnesses an ultrasound technology called histotripsy that can noninvasively destroy cancer tissue. Its Edison platform is now being used in eight of the top 10 U.S. cancer centers as well as more than 65 facilities worldwide. Having already received approval for the platform’s use in liver tumors, HistoSonics is conducting trials on other organs, particularly those where the clinical need is highest—the kidney, pancreas, and prostate. Investors believe in the potential: HistoSonics has raised more than $300 million over the last five years. “We are delivering on a vision to make surgery without incisions a clinical reality, providing new hope to a significant number of patients,” says Michael Blue, a medtech veteran who became HistoSonics’ leader in 2017. “What makes me bullish about 2026 and beyond is the response we’re seeing from both clinicians and patients—the enthusiasm and demand for our Edison platform across the world.”